Oral Supplement for Pregnant and Lactating Mothers

NCT ID: NCT01073033

Last Updated: 2012-09-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

234 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess protection against early life infections through supplementation of mothers during pregnancy to the newborns' growth, morbidity, immune status intra and extra-uterine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

During pregnancy mothers have to fulfill the tremendous physiological needs to support their own immune status as well as that of their babies. Accordingly, it appears highly valuable to provide mothers with a nutritional supplement during pregnancy and lactation to promote the immune development in newborns, thus reinforcing the infants' defenses.

In that respect, an appropriate maternal diet must provide sufficient energy and nutrients to meet the mother's usual requirements and promote health status, as well as the needs of the growing fetus and beyond for the neonate.

Key organogenesis steps take place during fetal life and many functional features of the immune system are already coded in the genetic asset of the individual. However, at birth the immune system remains fairly immature. An epigenetic, postnatal instruction seems to be extremely important for the maturation of the immune system allowing its full functionality.

The cross-talk between the mother and her baby is, indeed, crucial for the optimal development of the foetus and subsequently for the full and functional maturation of the neonate.

The newborn relies for his protection almost exclusively on his innate immune system that is initially instructed and educated early in life by factors derived from his mother as well as post-natal environmental factors such as early life colonization with micro-organisms that activates the innate immunity and enhance Th1-cell polarization thereby potentially reducing atopic dermatitis with respect to the hygiene hypothesis.

A large part of this immune education is provided by factors transmitted from the mother pre-natally through the placenta or post-natally via the breast milk. Breast milk contains a number of nutrients and bioactive components, including immune cells, maternal antibodies (mainly secretory IgA), cytokines, growth factors, lactoferrin, nucleotides, triacylglycerols, fatty acids, oligosaccharides, and vitamins. All together, these components beneficially impact the health status of the newborn, conferring, among other functions, immune education and early protection.

A typical example of such transfer of immune competence is the TGF-β that could be transmitted in active from either through the placenta or absorbed by the neonates through the milk. This TGF-β is an important IgA switch factor and this is likely to be responsible, in part, for the capacity of breast-fed infant to produce higher levels of mucosal SIgA compared to non-breast fed infants. Moreover, milk soluble CD14 transmitted to the newborn contributes to prime the neonatal gut to modulate the microbial recognition and establishment of endogenous microbiota.

Diarrhea episodes are major manifestation of common infant infections of viral or bacterial aetiology and are a key health concern in paediatrics. As mentioned above there are evidences that some probiotic strains significantly improve diarrheal outcomes in infants, particularly rotavirus diarrhea. In that respect diarrhea occurrence was selected as the primary outcome in the present trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diarrhea Acute Respiratory Infection

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

pregnancy lactation oral supplement probiotics early infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

oral supplement1

Oral supplement for pregnant and lactating mothers

Group Type EXPERIMENTAL

milk supplement 1

Intervention Type DIETARY_SUPPLEMENT

milk supplement with probiotics

oral supplement 2

Oral supplement for pregnant and lactating mothers

Group Type ACTIVE_COMPARATOR

milk supplement 2

Intervention Type DIETARY_SUPPLEMENT

milk supplement without probiotics

Reference

No oral supplementation during pregnancy and lactating.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

milk supplement 1

milk supplement with probiotics

Intervention Type DIETARY_SUPPLEMENT

milk supplement 2

milk supplement without probiotics

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Suitable for pregnant and lactating period. Suitable for pregnant and lactating periode.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Expecting mothers who are in their 6th month of pregnancy
* Willing to consume 2 x 200 ml of test product daily
* Willing to exclusively breastfeed until the baby is at least 2-month old
* Having signed the informed consent

Exclusion Criteria

* Known allergy to cow's milk
* Subjects previously diagnosed HIV(+) and Hepatitis B (+)
* Multiple pregnancy
* High risk pregnancy (pre-eclampsia, diabetes, etc)
* Currently participating or having participated in another clinical trial during the last 3 months
* Subjects who consumed pro- and /or prebiotics-containing food/supplement\* in the month before inclusion
Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of the Philippines

OTHER

Sponsor Role collaborator

Société des Produits Nestlé (SPN)

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr. Valerie Guinto, MD

Role: PRINCIPAL_INVESTIGATOR

University of the Philippines

Dr. Jacinto Mantaring, MD

Role: PRINCIPAL_INVESTIGATOR

University of the Philippines

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ospital Ng Muntinlupa

Manila, , Philippines

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Philippines

References

Explore related publications, articles, or registry entries linked to this study.

Mantaring J, Benyacoub J, Destura R, Pecquet S, Vidal K, Volger S, Guinto V. Effect of maternal supplement beverage with and without probiotics during pregnancy and lactation on maternal and infant health: a randomized controlled trial in the Philippines. BMC Pregnancy Childbirth. 2018 May 31;18(1):193. doi: 10.1186/s12884-018-1828-8.

Reference Type DERIVED
PMID: 29855271 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

08.10 INF

Identifier Type: -

Identifier Source: org_study_id